Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a top stock under $50 to consider buying now, with H.C. Wainwright raising the price target to $120 from $110, suggesting a 177% upside potential. The company’s preliminary 4Q25 and full-year 2025 financial results for VYKAT XR exceeded estimates, with full-year net revenue surpassing estimates by $16.5 million to $18.5 million and fourth-quarter net revenue expected to be between $90 and $92 million. Derek Archila from Wells Fargo also increased the price target to $114 from $106, noting the fourth-quarter revenue beat and favorable FY26 forecasts. Soleno Therapeutics, Inc. is a California-based biopharmaceutical company specializing in novel therapeutics, founded in 1999, offering Diazoxide Choline Extended-Release tablets.

Read more at Yahoo Finance: Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now?